Zovir

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zovir

Quick Facts: Zovir (Aciclovir)

Property Description
Active ingredient Aciclovir (Acyclovir)
Form Tablet, capsule, oral suspension, cream, ophthalmic ointment, IV infusion powder
Pharmacological class Antiviral agent (Anti-herpes agent)
General purpose Suppression of viral replication
Origin Synthetic purine nucleoside analogue

What is Zovir and Its Active Ingredient, Aciclovir?

Zovir is a trade name for a medication whose active component is the substance Aciclovir (INN), an agent clinically recognized for its pioneering role in targeted antiviral therapy. It is classified as an essential antiviral agent. This medication is fundamentally defined as a synthetic purine nucleoside analogue, meaning it is a laboratory-created compound that structurally mimics natural DNA building blocks, specifically a guanosine derivative. The composition of Zovir is based on this single active ingredient, making it a single-ingredient product (monotherapy).


Zovir's Pharmaceutical Forms and Delivery Types

Zovir, containing the active substance Aciclovir, is manufactured in multiple dosage forms to accommodate various therapeutic needs. The range of available preparations includes oral forms, such as the tablet, capsule, and oral suspension, intended for systemic absorption into the body. Forms for external or localized application are also produced, including the cream and ophthalmic ointment. Additionally, it is available as a powder for intravenous infusion, offering flexibility in the route of administration for acute or severe systemic intervention.


The General Purpose of Zovir's Antiviral Action

The primary purpose of Zovir is to suppress the pathogen's ability to multiply by selectively halting viral replication in infected cells. Aciclovir functions through a mechanism that only targets the multiplication process of the virus, limiting its ability to spread. This highly targeted function provides the specific benefit of managing the progression of infections by directly limiting the pathogen's capacity to spread. The therapeutic goal of Aciclovir is to act as a focused inhibitory agent against the causative virus.

What side effects are possible with Zovir?

Official Safety Profile of Zovir (Aciclovir)

The safety profile of Zovir, whose active ingredient is Aciclovir, is formally documented by regulatory authorities, classifying reported effects by their frequency and the physiological system affected. This structure defines the official understanding of possible adverse reactions.


Frequency-Classified Adverse Reactions

The following high-level adverse reactions are categorized based on their likelihood of occurrence in official regulatory documents:

Classification Examples of Adverse Reactions (Systemic Use)
Common (ge 1/100 to <1/10) Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, fatigue, rashes, and pruritus.
Rare (ge 1/10,000 to <1/1,000) Anaphylaxis, angioedema, and reversible increases in liver enzymes and bilirubin.
Very Rare (<1/10,000) Acute renal failure, hepatitis, jaundice, blood disorders (e.g., anemia, thrombocytopenia), and severe neurological effects (e.g., confusion, convulsions, coma).

Key Safety Constraints and Considerations

The regulatory profile identifies specific contexts requiring caution. Patients receiving systemic, high-dose Aciclovir—particularly the intravenous form—must maintain adequate hydration to help reduce the risk of renal toxicity. The medicine's clearance is reliant on kidney function; therefore, Older Adults and those with Renal Impairment are at an increased risk for developing CNS adverse reactions (e.g., confusion, tremor). These neurological events are generally documented as reversible upon discontinuation or dose adjustment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Zovir (acyclovir) based on two primary risks: serious renal toxicity and central nervous system (CNS) manifestations. Overdoses, particularly those involving high doses, have been officially documented to cause precipitation of the drug within the renal tubules, which can lead to elevated blood urea nitrogen (BUN) and serum creatinine, and subsequent acute renal failure.

CNS effects reported in overdose include life-threatening events such as agitation, lethargy, seizures, and coma. The risk of these severe CNS symptoms is noted to be increased in populations with pre-existing renal impairment or among older adults (geriatric patients).

When to Seek Immediate Medical Help

If an overdose is suspected, or if the individual has severe symptoms, immediate emergency action is required. Officially documented reasons to call for emergency services include if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.

Emergency Response

Treatment procedures officially described in regulatory labeling focus on supportive care and drug removal. This includes monitoring of fluid and electrolyte balance to prevent drug precipitation. In cases of severe renal failure and anuria (lack of urine production), hemodialysis is the documented procedure for drug removal until renal function is restored.

Therapeutic Uses of Zovir

The primary therapeutic domain of Zovir (Aciclovir) is to provide symptomatic support across a range of viral infections caused by the herpes virus family. The medication is commonly used to help lessen the symptoms of infection and support the healing of sores.

Zovir is applicable within clinical settings that involve acute or disruptive symptom patterns, including cold sores (Herpes Labialis), genital herpes, shingles (Herpes Zoster), chickenpox (Varicella), and severe infections like Herpes Simplex Encephalitis. This approach contributes to easing the overall symptom load during periods of heightened physical discomfort.

In these contexts, the medication assists with the management of symptoms such as painful blisters and sores, and may assist with the management of acute, localized sensations of burning and tingling.

“The primary purpose is to provide support that helps patients cope more steadily with difficult episodes by easing distress and assisting with maintaining functional stability.”

For patients experiencing recurrent episodes of genital herpes, Zovir is applied in a preventative or suppressive context, helping manage the frequency and severity of future outbreaks.


Quick Fact: Focus on Symptom Support Symptom Type Therapeutic Benefit
Blisters and Sores Supports healing and resolution of lesions
Pain and Sensations Assists with managing pain, burning, and itching
Outbreak Frequency Helps manage the frequency of future outbreaks

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zovir (Aciclovir) — Official Regulatory Information


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to aciclovir or valaciclovir (a prodrug).
Age-related eligibility rules Older adults are a population requiring special consideration due to a likelihood of reduced renal function. The safety and effectiveness of Zovir Cream are not established in pediatric patients younger than 12 years of age.
Condition-specific eligibility rules Use is conditional for patients with impaired renal function and requires close monitoring, as the drug's clearance depends on kidney function. Patients with dehydration must maintain adequate hydration.
Pregnancy and lactation eligibility status For pregnant women, systemic use is conditional and only considered if the potential benefit justifies the potential risk. Breastfeeding women are a conditional use group as the drug is excreted in breast milk.
Eligibility-related restrictions Caution is advised for patients with underlying neurological abnormalities. Application of Zovir Cream to human mucous membranes is not recommended.

Eligibility Classifications (High-Level)

Category Eligibility Severity Classification
Eligibility severity classification Absolute Contraindication (Hypersensitivity); Conditional Use/Precaution (Renal Impairment, Older Adults, Pregnancy/Lactation).

Resulting Eligibility Structure

Official eligibility statements:

  • The absolute contraindication for Zovir is known hypersensitivity to the active ingredient or valaciclovir.
  • Use is conditional for patients with impaired renal function, requiring special management due to the drug's dependence on kidney clearance.
  • Older adults are a conditional group who require close monitoring for neurological effects due to potential for reduced renal function.
  • Safety of Zovir Cream is not established in children under 12 years or for application to mucous membranes.

Connection to the overall eligibility profile:

Regulatory documents define eligibility through a single absolute exclusion (hypersensitivity) and multiple criteria for conditional use. These conditional criteria are primarily based on physiological status, such as renal function and age, to ensure the drug's safe processing and clearance from the body in vulnerable patient populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Information

The interaction profile for Zovir (Aciclovir) is primarily determined by its elimination pathway, which involves active renal tubular secretion in the kidneys. This mechanism creates the potential for pharmacokinetic interactions when Aciclovir is co-administered with other medications that use the same clearance system.

Interacting Substances and Outcomes

Interaction Type Interacting Substance(s) Official Regulatory Outcome
Renal Transporter Competition Probenecid, Mycophenolate Mofetil Increases Aciclovir plasma exposure (half-life and AUC) by reducing renal clearance.
Pharmacodynamic Risk Potentially Nephrotoxic Agents Increased risk of additive renal dysfunction (nephrotoxicity).
Pharmacodynamic Antagonism Talimogene laherparepvec May decrease the therapeutic effect of the co-administered viral therapy.

No medicinal product is formally designated as a drug-drug interaction contraindication in the primary regulatory labels. Oral forms of Aciclovir have no documented clinically significant interaction with food, alcohol, or common herbal products, and may be taken with or without meals. The risk of these documented interactions is heightened in elderly patients and individuals with pre-existing renal impairment, a population-specific consideration noted in regulatory labeling due to reduced baseline renal function.

Mechanism of Action

How Zovir Works: The Mechanism of Action

The pharmacological action of Aciclovir (Zovir) is highly specific, based on a mechanism that exploits the difference between viral and human enzyme systems to selectively restrict the process of viral multiplication.


Selective Activation by Viral Thymidine Kinase

The drug functions as a prodrug, requiring activation that is initiated primarily by the Viral Thymidine Kinase (TK) enzyme, which is encoded by the target virus. This dependence on a virus-specific enzyme ensures that Aciclovir is converted into its active, toxic form mainly within the infected cells, which defines the drug's selectivity for cells undergoing active viral replication.


Obligate Termination of Viral DNA Chain Synthesis

Once fully activated to Aciclovir triphosphate (ACV-TP), the molecule acts as a false nucleoside analogue. It is incorporated into the growing viral DNA strand by the Viral DNA Polymerase. Because the structure of ACV-TP lacks a necessary chemical group, its incorporation immediately and irreversibly halts the elongation of the DNA chain. This action effectively shuts down the viral DNA replication pathway, resulting in the limitation of new viral particle production at the cellular level.


Mechanistic Constraint: Inactivity Against Latency

The mechanism is intrinsically limited by the requirement for the virus to be actively replicating. When the virus is in a latent (dormant) state, it does not produce the necessary activating enzyme, Viral TK. Consequently, Aciclovir cannot be phosphorylated and remains inactive against the latent viral genetic material, meaning the drug's mechanism is only effective during periods of active viral replication.

Dosage and Administration Information

How Zovir is Used

Zovir (Aciclovir) administration is defined by its various pharmaceutical forms and the specific clinical context. The medication is administered via multiple routes: Oral (tablets, capsules, suspension), Intravenous (IV) Infusion, Topical (cream or ointment), and Ophthalmic Ointment.

Oral therapy for acute episodes, such as Herpes Zoster (shingles) or initial Genital Herpes, typically employs a high-frequency regimen of 200 mg to 800 mg per dose, taken five times daily. For long-term suppressive use, the regimen is usually 400 mg taken twice daily. Treatment duration is short-course for acute infections, generally lasting 5 to 10 days, or up to 12 months for suppressive therapy, followed by re-evaluation.

Administration Conditions and Adjustments

Oral forms may be taken with or without food but must be accompanied by adequate fluid intake, such as a full glass of water, to promote renal function. Treatment should be initiated as early as possible at the first sign of symptoms (prodrome or lesion onset).

Topical cream is applied externally five times daily and should be applied using a finger cot or glove to prevent the transfer of the virus.

Dosing for Specific Populations

Dose adjustment is required for patients with renal impairment, with the dose and/or interval being modified based on the patient's creatinine clearance. Similarly, older adults may require dose reduction due to the common reduction in kidney function associated with age. For severe systemic infections, the IV infusion must be diluted and administered slowly over a minimum of one hour.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zovir (Aciclovir)

This section provides a summary of the clinical research and study designs used in the evaluation of Zovir (Aciclovir) according to regulatory and scientific literature. The purpose is to describe the available evidence, not to offer treatment advice or predict individual outcomes.


Evidence for Treating Cold Sores (Herpes Labialis) and Genital Herpes

Research examining Zovir for cold sores and genital herpes has primarily involved Randomized Controlled Trials (RCTs), used in research exploring how episodic or acute changes in symptoms are managed. For acute episodes, studies monitored the time to complete healing of lesions, the duration of associated pain, and the length of time the virus was shed. Studies report measurements showing a shorter period of active symptoms was observed compared to controls when treatment was initiated early. For cold sores, research reports that the measured changes in healing time were sometimes small. Outcomes were highly sensitive to the time of treatment initiation, and long-term outcomes are not fully characterized.


Evidence for Treating Shingles (Herpes Zoster) and Chickenpox (Varicella)

For shingles, RCTs monitored the time to rash healing, the time until zoster-associated pain ceased, and the incidence of Postherpetic Neuralgia (PHN) at 3 and 6 months. Research reports that early initiation of treatment was associated with a shorter duration of acute pain, and studies monitored patterns related to the development of PHN. Research for chickenpox focused on pediatric populations, where studies report that a reduced duration of fever was observed in the treated groups. However, much of the existing clinical trial data is not contemporary, and research provides limited insight into outcomes such as itchiness.


Evidence in Specific Patient Populations and Uncertainty

Studies have evaluated Zovir in special groups, including pediatric patients (children), older adults (particularly for shingles), and immunocompromised patients. For the latter, studies report measurements related to reduced dissemination and severity, although they noted that the isolation of resistant virus types was observed more frequently in some immunocompromised populations.

Research highlights that long-term data regarding outcomes after several years of continuous suppressive use are not fully established. Additionally, comparative evidence against all alternative antiviral options is lacking for every single indication. Findings describe group patterns related to symptom management; study results reflect the specific conditions under which they were conducted and do not provide individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Zovir (FAQ)


Q: Is Zovir the same as other medicines with a similar name?

Zovir is a specific brand name for the antiviral medicine aciclovir. Generic versions containing the same active ingredient are available and must meet the same regulatory standards as the brand-name product. Official prescribing information also notes that the drug valaciclovir is closely related, and known hypersensitivity to either medicine is a contraindication for using Zovir.


Q: Do I need a prescription to get Zovir?

The regulatory classification of Zovir depends on the specific product form and local requirements. Most forms intended for systemic use, such as the oral tablets and IV preparation, are classified as Prescription Only Medicine and require authorization from a healthcare provider. However, certain low-concentration topical creams may be available without a prescription in some regions.


Q: What happens if I miss a dose of Zovir?

Official regulatory documents do not contain specific, step-by-step instructions for managing individual instances of a missed dose. If a dose is forgotten, official documents recommend consulting a healthcare provider for personalized guidance regarding a missed dose, rather than providing generalized advice.


Q: Does Zovir interact with pain relievers like ibuprofen or acetaminophen?

Clinical experience has not identified a formal, clinically significant interaction between aciclovir and most commonly used over-the-counter pain relievers. However, the regulatory profile notes that special consideration is required when aciclovir is used with other medicines that compete for clearance through the kidneys or are known to potentially affect kidney function.


Q: Is Zovir addictive in any way?

Aciclovir, the active ingredient in Zovir, is classified by regulatory authorities as Not a controlled medication. This classification indicates that the medicine has no recognized potential for dependence or abuse.


Q: What should I do if I think I'm having a serious side effect from Zovir?

Regulatory guidance specifies that if a patient experiences severe or troublesome side effects, professional medical attention should be sought. Official guidance also details the process for reporting serious adverse events directly to the appropriate regulatory agency, such as the FDA MedWatch program.


Q: How long does Zovir stay in your system after stopping treatment?

The time Zovir remains in the system is dependent on an individual's renal function, which refers to how well the kidneys are working. The drug is primarily cleared from the body by the kidneys, and this elimination process is characterized by its half-life in the bloodstream.


Q: How does Zovir compare to generic versions of the drug?

Generic versions of the active ingredient, aciclovir, are widely available. Regulatory agencies require that generics possess the same active ingredient, strength, and dosage form as the brand-name product they mimic. This ensures the generic is comparable to Zovir in terms of drug content and delivery.


Q: Can Zovir be taken with a multivitamin?

Official prescribing information indicates that oral aciclovir has no documented clinically significant interaction with food or common herbal products. While specific interactions with every component of a multivitamin are not formally listed, the primary regulatory focus is on interactions related to kidney clearance, and the known interaction profile remains otherwise limited.


Q: Does Zovir change the contagiousness of the condition it treats?

Regulatory labeling states that Zovir is not a cure for the viral infections it treats. Furthermore, official information explicitly states there are no data evaluating whether it will prevent transmission of infection to others, meaning transmission can still occur even while taking the medication.


Q: What is the difference between Zovir and similar-sounding over-the-counter creams?

Zovir is the brand name for the active ingredient aciclovir. Some over-the-counter (OTC) products for cold sores and similar issues contain different active substances, such as docosanol. The regulatory status of aciclovir itself—whether prescription or OTC—is dependent on the specific product form and the country's local regulations.


Q: Are there any specific laboratory tests that might be affected by Zovir?

Official regulatory documents report that aciclovir is known to cause changes in certain laboratory tests. These effects include reversible increases in liver enzymes and bilirubin, as well as increases in blood urea and creatinine, which are listed as rare adverse reactions.


Q: Is Zovir gluten-free or lactose-free?

The inactive ingredients, or excipients, in Zovir can vary depending on the specific product form and manufacturer. Official prescribing information states that some oral forms may contain lactose monohydrate. For patients with specific intolerances, the official excipient list is available for review in the product information.


Q: Does taking Zovir make you more sensitive to the sun?

The regulatory safety profile for aciclovir lists various skin reactions. Among these, photosensitivity, which is a heightened sensitivity to light or sun exposure, is listed as an Uncommon adverse reaction in official product information.


Q: Is Zovir a drug that has had recent safety updates from the FDA or EMA?

Official drug information is regularly reviewed and updated by regulatory agencies like the FDA and EMA to reflect the latest safety and efficacy data. For instance, the European Summary of Product Characteristics (SmPC) includes the date of the last full review to document the currency of the information.


Q: What happens if Zovir is taken by someone who doesn't need it?

Official documentation notes that aciclovir should only be taken when prescribed by a healthcare professional. Regulatory documents highlight that accidental overdose has been associated with severe reactions, including elevations in serum creatinine, acute renal failure, and neurological effects such as confusion or seizures.

How should Zovir be stored and disposed of?

The official storage and disposal requirements for Zovir (aciclovir) vary based on its pharmaceutical form.


Storage and Handling Requirements

Product Form Temperature & Protection Stability Constraint
Tablets Store at 20° to 25°C. Protect from moisture. None specified for unopened packaging.
Cream Store below 25°C. Do not refrigerate or freeze. None specified for unopened packaging.
Oral Suspension Store below 25°C. Discard after one month of first opening.
IV Powder Store below 25°C. Protect from light in outer carton. Use reconstituted solution within 12 hours.

All forms of Zovir must be stored out of the sight and reach of children.


Disposal Instructions

Unused Zovir must be disposed of according to local requirements. The medicine should not be disposed of via wastewater or household waste, necessitating use of authorized pharmaceutical waste collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zovir found in:

A-Z Index: